论文部分内容阅读
目的探讨乙型肝炎病毒(HBV)不同基因型及乙型肝炎e抗原(HBeAg)对聚乙二醇干扰素治疗慢性乙型肝炎(CHB)应答率的影响。方法采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP) 方法,分析42例用聚乙二醇干扰素治疗的CHB患者基因型及HBeAg不同状态时对抗病毒治疗的影响。结果不同基因型对聚乙二醇干扰素的应笞率不同,B基因型的持续应答率为66.7%(12/18),C基因型持续应答率为27.3%(3/11)。HBeAg阴性患者的持续应答率为87.5%(7/8),HBeAg阳性患者为38.1%(8/21), P<0.05。结论HBV基因型及HBeAg的不同状态是预测聚乙二醇干扰素疗效的重要因素,且后者比前者的意义更大。
Objective To investigate the effect of different genotypes of hepatitis B virus (HBV) and HBeAg on the response rate of pegylated interferon to chronic hepatitis B (CHB). Methods The genotypes of 42 CHB patients treated with pegylated interferon (IFN) and the effect of anti-virus treatment in different states of HBeAg were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results The response rates of different genotypes to peginterferon were different. The sustained response rate of B genotype was 66.7% (12/18) and that of C genotype was 27.3% (3/11). The sustained response rate was 87.5% (7/8) in HBeAg-negative patients and 38.1% (8/21) in HBeAg-positive patients, P <0.05. Conclusion The different genotypes of HBV and HBeAg are important predictors of the efficacy of pegylated interferon, and the latter is of greater significance than the former.